Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.

dc.contributor.author

Allott, EH

dc.contributor.author

Howard, LE

dc.contributor.author

Cooperberg, MR

dc.contributor.author

Kane, CJ

dc.contributor.author

Aronson, WJ

dc.contributor.author

Terris, MK

dc.contributor.author

Amling, CL

dc.contributor.author

Freedland, SJ

dc.coverage.spatial

England

dc.date.accessioned

2014-05-06T14:09:01Z

dc.date.issued

2014-11

dc.description.abstract

OBJECTIVE: To investigate the effect of statin use after radical prostatectomy (RP) on biochemical recurrence (BCR) in patients with prostate cancer who never received statins before RP. PATIENTS AND METHODS: We conducted a retrospective analysis of 1146 RP patients within the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Multivariable Cox proportional hazards analyses were used to examine differences in risk of BCR between post-RP statin users vs nonusers. To account for varying start dates and duration of statin use during follow-up, post-RP statin use was treated as a time-dependent variable. In a secondary analysis, models were stratified by race to examine the association of post-RP statin use with BCR among black and non-black men. RESULTS: After adjusting for clinical and pathological characteristics, post-RP statin use was significantly associated with 36% reduced risk of BCR (hazard ratio [HR] 0.64, 95% confidence interval [CI] 0.47-0.87; P = 0.004). Post-RP statin use remained associated with reduced risk of BCR after adjusting for preoperative serum cholesterol levels. In secondary analysis, after stratification by race, this protective association was significant in non-black (HR 0.49, 95% CI 0.32-0.75; P = 0.001) but not black men (HR 0.82, 95% CI 0.53-1.28; P = 0.384). CONCLUSION: In this retrospective cohort of men undergoing RP, post-RP statin use was significantly associated with reduced risk of BCR. Whether the association between post-RP statin use and BCR differs by race requires further study. Given these findings, coupled with other studies suggesting that statins may reduce risk of advanced prostate cancer, randomised controlled trials are warranted to formally test the hypothesis that statins slow prostate cancer progression.

dc.identifier

http://www.ncbi.nlm.nih.gov/pubmed/24588774

dc.identifier.eissn

1464-410X

dc.identifier.uri

https://hdl.handle.net/10161/8617

dc.language

eng

dc.publisher

Wiley

dc.relation.ispartof

BJU Int

dc.relation.isversionof

10.1111/bju.12720

dc.subject

biochemical recurrence

dc.subject

cholesterol

dc.subject

postoperative statin use

dc.subject

prostate cancer

dc.subject

Aged

dc.subject

Databases, Factual

dc.subject

Humans

dc.subject

Hydroxymethylglutaryl-CoA Reductase Inhibitors

dc.subject

Male

dc.subject

Middle Aged

dc.subject

Neoplasm Recurrence, Local

dc.subject

Postoperative Period

dc.subject

Proportional Hazards Models

dc.subject

Prostatectomy

dc.subject

Prostatic Neoplasms

dc.subject

Retrospective Studies

dc.subject

Risk

dc.subject

United States

dc.title

Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.

dc.type

Journal article

duke.contributor.orcid

Howard, LE|0000-0003-3355-4483

pubs.author-url

http://www.ncbi.nlm.nih.gov/pubmed/24588774

pubs.begin-page

661

pubs.end-page

666

pubs.issue

5

pubs.organisational-group

Duke

pubs.organisational-group

Staff

pubs.publication-status

Published

pubs.volume

114

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Allott_postoperative statin use and prostate cancer recurrence.pdf
Size:
394.72 KB
Format:
Adobe Portable Document Format
Description:
Submitted version